1Cademy - Patient characteristics in study evaluating heparin effectiveness in COVID-19 patients for patients at high risk of coagulopathy from retrospective study in Wuhan, China

Learn Before

Findings supporting heparin use in COVID-19 patients for patients at high risk of coagulopathy from retrospective study in Wuhan, China

Concept

Patient characteristics in study evaluating heparin effectiveness in COVID-19 patients for patients at high risk of coagulopathy from retrospective study in Wuhan, China

enrolled 449 patients (181 females and 268 males) with severe COVID-19
mean age at disease onset was 65.1 ± 12.0 years
272 (60.6%) patients had chronic disease, most commonly hypertension (n = 177, 39.4%), diabetes (n = 93, 20.7%), and heart diseases (n = 41, 9.1%)
99(22.0%) patients received heparin treatment for at least 7 days, in which 94 received LMWH (40‐60 mg enoxaparin/d) and five received unfractionated heparin (10 000‐15 000 U/d)
patients received other treatments as part of recommended COVID-19 treatment (antivirals, supportive therapy, etc.)
"97(21.6%) patients met the SIC criteria (total score ≥ 4) when they were classified as severe cases."
"By the end of March 13, 315 (70.2%) patients were still survived and 134 (29.8%) patients had died (Figure 1)."